Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$76.64

-2.39 (-3.02%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31

Neurocrine initiated with an Outperform at Credit Suisse

Credit Suisse analyst Evan Seigerman initiated Neurocrine with an Outperform rating and a $95 price target, calling the stock a Top Pick - SMID Cap. Seigerman believes Neurocrine's Ingrezza is "the best-in-class treatment" for tardive dyskinesia, or TD, and he expects it will drive revenue and earnings growth over the next few years. He also believes the company's pipeline has underappreciated upside potential, with assets for Parkinson's disease and congenital adrenal hyperplasia.

  • 22

    May

NBIX Neurocrine
$76.64

-2.39 (-3.02%)

04/22/19
JPMS
04/22/19
UPGRADE
Target $106
JPMS
Overweight
JPMorgan upgrades Neurocrine to Overweight after 15% pullback
JPMorgan analyst Anupam Rama upgraded Neurocrine Biosciences to Overweight from Neutral and raised his price target for the shares to $106 from $100. The stock is down ~15% from the mid-January highs, Rama tells investors in a research note. The analyst, however, says his "multiple proprietary analyses" since January "underscore the solid fundamentals of Neurocrine," For example, his March U.S. tardive dyskinesia physician survey shows a preference for Ingrezza over Austedo, anticipated overall branded market growth, and Ingrezza continuing to gain dominant market share over the next 12-24 months. Further, Rama believes the Q1 consensus estimate for Ingrezza could be beatable.
04/26/19
EVER
04/26/19
NO CHANGE
EVER
Neurocrine shares defended at Evercore ISI
04/29/19
CANT
04/29/19
NO CHANGE
Target $127
CANT
Overweight
Neurocrine selloff an opportunity for 'several reasons,' says Cantor Fitzgerald
Neurocrine Biosciences recently traded lower as Ingrezza was put on updated 2019 National Preferred Formulary exclusions list that Express Scripts (ESRX) published, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. The analyst sees the selloff as an "opportunity for longer-horizon investors for several reasons." The exclusion is not immediate, and will also have little impact on Ingrezza sales as Express Scripts accounts for less than 1% of the drugs revenue, Duncan writes. He believes Ingrezza will continue to grow with "deepening penetration" of the tardive dyskinesia market as the "pharmaco-economic benefits continue to be realized." The analyst reiterates an Overweight rating on Neurocrine with a $127 price target.
05/14/19
LEHM
05/14/19
NO CHANGE
Target $25
LEHM
Overweight
Myovant Sciences selloff overdone after report of relugolix data, says Barclays
Barclays analyst Geoffrey Meacham said he thinks the selloff in shares of Myovant Sciences (MYOV) is overdone after the release of relugolix phase 3 uterine fibroids data. He believes investors are "selling the news" and he still believes relugolix has a comparable profile to AbbVie (ABBV) and Neurocrine's (NBIX) elagolix and will find a place in the market given what he sees as positive data reported this morning, Meacham tells investors. He keeps an Overweight rating and $25 price target on Myovant shares, which are down 26% to $12.67 in early afternoon trading.

TODAY'S FREE FLY STORIES

03:45
07/22/19
07/22
03:45
07/22/19
03:45
General news
FX Action: USD-CAD has found a footing »

FX Action: USD-CAD has…

03:00
07/22/19
07/22
03:00
07/22/19
03:00
General news
FX Update: The dollar has remained underpinned »

FX Update: The dollar has…

02:05
07/22/19
07/22
02:05
07/22/19
02:05
General news
Asian Market Wrap: »

Asian Market Wrap:…

ASOMY

Asos

$0.00

(0.00%)

21:13
07/21/19
07/21
21:13
07/21/19
21:13
Downgrade
Asos rating change at JPMorgan »

Asos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLAC

KLA-Tencor

$131.95

-1.5 (-1.12%)

21:12
07/21/19
07/21
21:12
07/21/19
21:12
Upgrade
KLA-Tencor rating change at Goldman Sachs »

KLA-Tencor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

LRCX

Lam Research

$198.43

0.19 (0.10%)

21:07
07/21/19
07/21
21:07
07/21/19
21:07
Upgrade
Lam Research rating change at Goldman Sachs »

Lam Research upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MRVL

Marvell

$25.90

-0.48 (-1.82%)

21:07
07/21/19
07/21
21:07
07/21/19
21:07
Downgrade
Marvell rating change at Goldman Sachs »

Marvell downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$47.79

-0.38 (-0.79%)

21:05
07/21/19
07/21
21:05
07/21/19
21:05
Upgrade
Applied Materials rating change at Goldman Sachs »

Applied Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$45.51

0.85 (1.90%)

21:04
07/21/19
07/21
21:04
07/21/19
21:04
Upgrade
Goldman Sachs more positive on memory stocks, upgrades Micron to Buy »

Goldman Sachs analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEYS

Keysight Technologies

$87.43

0.05 (0.06%)

20:49
07/21/19
07/21
20:49
07/21/19
20:49
Downgrade
Keysight Technologies rating change at Goldman Sachs »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BYND

Beyond Meat

$176.65

6.28 (3.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

19:30
07/21/19
07/21
19:30
07/21/19
19:30
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

BYND

Beyond Meat

$176.65

6.28 (3.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

DIS

Disney

$139.86

-1.76 (-1.24%)

NFLX

Netflix

$315.10

-10.04 (-3.09%)

T

AT&T

$32.77

-0.32 (-0.97%)

CBS

CBS

$50.68

-0.66 (-1.29%)

FDX

FedEx

$167.08

1.69 (1.02%)

EFX

Equifax

$137.29

-2 (-1.44%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

V

Visa

$179.18

-1.34 (-0.74%)

PYPL

PayPal

$118.65

-1.22 (-1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 31

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 12

    Aug

  • 21

    Aug

  • 29

    Aug

  • 17

    Sep

  • 19

    Sep

  • 25

    Sep

  • 16

    Oct

  • 13

    Nov

T

AT&T

$32.77

-0.32 (-0.97%)

, CMCSA

Comcast

$44.06

-0.5 (-1.12%)

18:23
07/21/19
07/21
18:23
07/21/19
18:23
On The Fly
Box Office Battle: 'The Lion King' roars to number 1 in $185M U.S. debut »

"Box Office Battle" is…

T

AT&T

$32.77

-0.32 (-0.97%)

CMCSA

Comcast

$44.06

-0.5 (-1.12%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$53.68

-0.275 (-0.51%)

LGF.A

Lionsgate

$11.94

0.36 (3.11%)

DIS

Disney

$139.86

-1.76 (-1.24%)

VIAB

Viacom

$30.48

-0.11 (-0.36%)

VIA

Viacom

$35.24

0.24 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

EFX

Equifax

$137.29

-2 (-1.44%)

17:23
07/21/19
07/21
17:23
07/21/19
17:23
Periodicals
Equifax agrees to pay $700M after massive data breach, WSJ reports »

Equifax is nearing a deal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 06

    Aug

  • 12

    Aug

  • 13

    Nov

CBS

CBS

$50.68

-0.66 (-1.29%)

, T

AT&T

$32.77

-0.32 (-0.97%)

17:17
07/21/19
07/21
17:17
07/21/19
17:17
Periodicals
AT&T drops CBS channels from cable systems, Reuters reports »

CBS (CBS) and AT&T…

CBS

CBS

$50.68

-0.66 (-1.29%)

T

AT&T

$32.77

-0.32 (-0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 30

    Jul

  • 08

    Aug

  • 08

    Aug

NFLX

Netflix

$315.10

-10.04 (-3.09%)

17:11
07/21/19
07/21
17:11
07/21/19
17:11
Periodicals
Netflix signs first direct agreement with SAG-AFTRA, Bloomberg reports »

Netflix and the Screen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

17:08
07/21/19
07/21
17:08
07/21/19
17:08
Periodicals
Johnson & Johnson facing key test in talc-safety lawsuits, WSJ reports »

Johnson & Johnson,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

MRKR

Marker Therapeutics

$6.28

-2.4 (-27.65%)

16:46
07/21/19
07/21
16:46
07/21/19
16:46
Hot Stocks
Marker Therapeutics reports interim results of MultiTAA T Cell Therapy »

Marker Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 09

    Sep

RDY

Dr. Reddy's

$37.73

-0.6 (-1.57%)

16:41
07/21/19
07/21
16:41
07/21/19
16:41
Hot Stocks
Dr. Reddy's announces transaction closure to divest Zembrace Symtouch, Tosymra »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

KLAC

KLA-Tencor

$131.95

-1.5 (-1.12%)

16:37
07/21/19
07/21
16:37
07/21/19
16:37
Upgrade
KLA-Tencor rating change at Goldman Sachs »

KLA-Tencor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

LRCX

Lam Research

$198.43

0.19 (0.10%)

16:33
07/21/19
07/21
16:33
07/21/19
16:33
Upgrade
Lam Research rating change at Goldman Sachs »

Lam Research upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MRVL

Marvell

$25.90

-0.48 (-1.82%)

16:30
07/21/19
07/21
16:30
07/21/19
16:30
Downgrade
Marvell rating change at Goldman Sachs »

Marvell downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEYS

Keysight Technologies

$87.43

0.05 (0.06%)

16:29
07/21/19
07/21
16:29
07/21/19
16:29
Downgrade
Keysight Technologies rating change at Goldman Sachs »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$45.51

0.85 (1.90%)

16:26
07/21/19
07/21
16:26
07/21/19
16:26
Upgrade
Micron rating change at Goldman Sachs »

Micron upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCEHY

Tencent

$0.00

(0.00%)

, MDLA

Medallia

$37.09

(0.00%)

07:31
07/21/19
07/21
07:31
07/21/19
07:31
On The Fly
Opening Day: Start-up DouYou becomes China's biggest Wall Street IPO of 2019 »

Drugmaker Genmab raised…

TCEHY

Tencent

$0.00

(0.00%)

MDLA

Medallia

$37.09

(0.00%)

MIRM

Mirum Pharmaceuticals

$13.51

0.17 (1.27%)

FULC

Fulcrum Therapeutics

$12.49

-0.99 (-7.34%)

PHR

Phreesia

$24.01

-1.15 (-4.57%)

GMAB

Genmab

$18.06

-0.14 (-0.77%)

AMK

AssetMark Financial

$27.71

0.39 (1.43%)

ORCC

Owl Rock

$15.51

0.11 (0.71%)

DOYU

DouYu

$10.50

-0.51 (-4.63%)

NOVA

Sunnova Energy

$0.00

(0.00%)

CSTL

Castle Biosciences

$0.00

(0.00%)

WSG

Wanda Sports

$0.00

(0.00%)

LVGO

Livongo Health

$0.00

(0.00%)

HCAT

Health Catalyst

$0.00

(0.00%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 31

    Jul

  • 14

    Aug

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.